Paediatric human immunodeficiency virus (HIV) infection
remains a significant concern, with an estimated 150 000 children newly infected with HIV in 2015. 1 Most children acquire HIV through vertical transmission, including transmission of the virus in utero, at birth, or through breastfeeding. The virus is thought to penetrate the central nervous system (CNS) of the developing fetus or infant early in infection, forming a CNS reservoir of HIV that is distinct from viral load within the plasma. 2, 3 In some cases, neurological damage and malfunction may subsequently occur, with postulated mechanisms including interaction of the virus with brain macrophages and microglia, and an immune-mediated inflammatory cascade. 4, 5 The most common primary manifestation of HIV CNS infection is HIV encephalopathy (HIVE), an acquired immunodeficiency syndrome-defining illness diagnosed according to at least one of the following Centres for Disease Control criteria, present for at least 2 months: (1) failure to attain developmental milestones or loss of those previously attained; (2) impaired brain growth or acquired microcephaly; and (3) motor deficits, such as pathological reflexes or gait disturbances. 6 Although the reasons for some children infected with HIV developing HIVE -and others notremain unclear, high baseline viral load has been identified as a factor that may increase the risk of developing HIVE. 7, 8 Antiretroviral therapy (ART) substantially reduces the incidence of HIVE and may delay onset and improve neurological outcomes in those cases that do occur. 7, 9, 10 However, not all children infected with HIV have access to ART, or may not have commenced ART early enough to protect against neurological complications.
11 These and other factors may, in part, explain why HIVE remains a concern in resource-limited settings, including South Africa. [12] [13] [14] For example, 87 of 145 children assessed at a dedicated HIV neurology clinic at the Red Cross War Memorial Children's Hospital, Cape Town, South Africa between 2008 and 2012 were diagnosed with HIVE, according to Centers for Disease Control criteria. 12 Furthermore, 55 (63%) of the children had bilateral lower limb (BLL) spasticity as part of the HIVE diagnosis. 12 Previous reports suggest that presentation of HIVEassociated BLL spasticity may range from mild hypertonia to severe spasticity. 7, 9, 15 However, there has been little description of functional status in these children, or which factors determine the relative severity of the spasticity. Langerak et al. 15 described gait patterns in children with HIVE and BLL spasticity and reported later initiation of ART in a group with pronounced pathological gait patterns compared with a group with only limited abnormalities. However, these differences were not analysed statistically and the possible association between ART initiation and functional status remains unclear. Further insight into the functional status of children with HIVE and BLL spasticity may have direct implications for clinical practice. Therefore, the aims of the current study were (1) to describe the functional status of ambulant children with HIVE and BLL spasticity receiving current standard of care, and (2) to investigate the association between current functional status and ART initiation, including age, CD4 percentage, and viral load values at ART initiation.
METHOD Participants
Children with BLL spasticity were identified using a database from a dedicated HIV neurology clinic at Red Cross War Memorial Children's Hospital, from special needs schools within the Cape Town area and from clinician referrals at Red Cross War Memorial Children's Hospital and at Tygerberg Hospital. Medical records were subsequently reviewed to assess whether each child was eligible to participate in the study, according to the following inclusion criteria: (1) diagnosis of HIVE according to Centers for Disease Control criteria; (2) aged 5 to 12 years; (3) ambulant with or without the use of walking aids. Exclusion criteria included: (1) significant prematurity (birth weight of ≤2.0kg and/or a gestational age of ≤35wks); (2) additional neuromuscular or CNS disorders (e.g. tuberculosis meningitis); (3) botulinum neurotoxin treatment within the last 6 months; (4) surgery on the lower limbs within the last 12 months. Caregivers of children potentially eligible for the study were contacted and invited to attend a screening session at the hospital, which included a physical examination. This physical examination was conducted by a highly experienced physiotherapist and involved an assessment of muscle tone in the hip flexor, rectus femoris, hamstring, adductor, and plantar flexor muscles. A child who had bilateral increased muscle tone in one or more of these muscle groups was considered to have BLL spasticity.
The study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC 447/ 2012) and by Red Cross War Memorial Children's Hospital. Each caregiver provided informed consent prior to their child's participation, and assent was obtained from the participants themselves. An isiXhosa translator assisted with obtaining consent or completing questionnaires with the caregiver and assessments with the participant, as necessary.
Outcome measures
Clinical and demographic background information was obtained through a review of medical records and an interview with each participant's caregiver. Housing density, as an indicator of socioeconomic status, was taken as the number of rooms in the home (excluding the kitchen and bathroom) divided by the number of people living in the home. 16 Functional status was described by classifying each participant according to the Gross Motor Functional Classification System (GMFCS), 17, 18 and by performing the 88-item Gross Motor Function Measure (GMFM-88). The GMFCS is a five-level scale conventionally used to describe functional status in children with cerebral palsy. 17 The GMFM-88 is a valid and reliable tool for assessing functional status in children with cerebral palsy, 19, 20 and assesses activity in five domains: (1) 'Lying and Rolling'; (2) 'Sitting'; (3) 'Crawling and Kneeling'; (4) 'Standing'; (5) 'Walking, Running, and Jumping'. Scores for each activity domain are expressed as a percentage of the maximum possible score for the domain and total GMFM-88 score as the average percentage score across the five domains. All scores were calculated using the Gross Motor Ability Estimator application version 1.3 (www.canchild.ca).
Timing of the start of ART and current ART regimen was obtained from medical records and confirmed with the caregiver wherever possible. Furthermore, a record of all available CD4 and viral load results for each participant was obtained from the South African National Health Laboratory Service. In a South African setting, blood tests for ART monitoring are typically performed on an annual basis, but they may be more frequent if there are treatment concerns or less frequent if patients are temporarily lost to follow-up. Although a CD4 analysis is always performed, a viral load analysis may or may not be included. Start of ART CD4 or viral load values were taken as the blood test result closest to the start of ART date up to a maximum of 3 months post-initiation of ART. Viral load suppression was taken as two consecutive viral load results of less than 400 copies/ml, obtained 3 to 18 months apart.
Statistical analysis
All data are presented as median (interquartile range [IQR]), unless otherwise indicated. For some analyses, participants were grouped according to GMFCS levels I, II, and III, and the GMFCS levels compared using a KruskalWallis test and Multiple Comparisons of Mean Ranks post-hoc test. However, to investigate associations between the GMFM and ART-related variables, a Spearman's rank correlation was performed using the pooled group of all participants with HIVE. All statistical analyses were performed using Statistica (version 12; Dell, Round Rock, TX, USA) or GraphPad Prism (version 6.00; GraphPad, La Jolla, CA, USA) with significance accepted at p<0.05.
What this paper adds
• Gross motor function limitations associated with human immunodeficiency virus encephalopathy and bilateral lower limb spasticity range from mild to severe.
• Age, CD4 percentage, or viral load at initiation of antiretroviral therapy are not predictive factors for functional status.
RESULTS

Participant characteristics
Thirty children with HIVE and BLL spasticity were recruited (14 males, 16 females). Participant demographic information, ART descriptors, and interventions are presented in Table I . Five children were excluded from start of ART CD4 analyses, and eight were excluded from start of ART viral load analyses because appropriate blood test results were not available.
Gross motor function
Scores for each activity domain of the GMFM-88, as well as the total GMFM-88 scores, are shown in Table SI (online supporting information). All participants performed well in the 'Lying and Rolling', 'Sitting', and 'Crawling and Kneeling' domains, with median scores of 95% to 100%. However, many participants had much lower scores for the 'Standing' and 'Walking, Running, and Jumping' components of the GMFM-88, and there was substantial variation in score for these domains. Lowest and highest scores ranged from 26% to 97% for the 'Standing' domain and from 8% to 99% for the 'Walking, Running, and Jumping' domain, contributing to an overall range of 62% to 99% for the total GMFM-88 score. Figure 1 shows the ART initiation factors of age (Fig. 1a) , CD4 percentage (Fig. 1b) , and viral load (Fig. 1c) relative to GMFM-88 score. No significant associations between ART initiation factors and GMFM-88 were detected in the current cohort (p>0.100). ART initiation factors were also compared between GMFCS levels ( Fig. 1d-f) , and participants were individually ranked according to age at start of ART, CD4 percentage, or viral load (Fig. 1g-i) . However, no noticeable patterns were observed.
ART initiation and current functional status
DISCUSSION
It has been well-documented that BLL spasticity may form part of a diagnosis of HIVE. 7, 9, 15 However, the current study is the first to describe the functional status of ambulant children with HIVE and BLL spasticity and to investigate an association between ART initiation factors and current functional status. The first finding of the study was that children with HIVE and BLL spasticity showed substantial variation in functional status. The participant group was more or less evenly distributed between children with GMFCS level I, II, and III, and total GMFM-88 scores ranged from 62% to 99%. Variation in the total GMFM-88 score arose primarily from varying ability within the 'Standing' and 'Walking, Running, and Jumping' domains, with individual scores ranging from of 26% to 97% and from 8% to 99% respectively.
Previous studies have alluded to variation in the relative severity of BLL spasticity associated with HIVE, 7, 9 and the first description of physical status and gait patterns in this population was published recently. 15 However, physical impairments do not necessarily reflect functional status. For example, Ross and Engsberg found no significant association between the severity of spasticity in the lower limb muscles and performance in the 66-item GMFM in children with bilateral spastic cerebral palsy. 21 Therefore, the current observations of mild-to-severe limitations in standing-, walking-, running-, and jumping-related activities offer important practical insight into the day-to-day functioning of children with HIVE and BLL spasticity.
The second finding of the study was that no associations were detected between age, CD4 percentage, or viral load at the start of ART and current functional status among the participant group (Fig. 1a-c) . However, it is important to note that this finding was based on a small sample, likely underpowered to detect relationships. In other words, it cannot necessarily be concluded that ART initiation is not clinically significant for subsequent functional status. With regard to age at start of ART, it was noted that children at GMFCS level III initiated ART at a median age of 13 months, whereas children at GMFCS level I or II initiated ART at a median age of 6 to 7 Table I : Clinical, demographic, and antiretroviral therapy (ART) information for study participants
Clinical and demographic information Median (IQR) age, y 7 (7-9) 9 (8-11) 9 (7-12) 8 (7-11) Male, n (%)
7 ( b GMFCS I, n=9; GMFCS II, n=9; GMFCS III, n=7; total HIVE, n=25.
c GMFCS I, n=9; GMFCS II, n=8; GMFCS III, n=5; total HIVE, n=22 GMFCS, Gross Motor Function Classification System; HIVE, human immunodeficiency virus encephalopathy; IQR, interquartile range; SES, socioeconomic status; LDL, lower than detectable level. months (Table I) . This observation is similar to that of Langerak et al., 15 who found that children with HIVE and BLL who had pathological gait patterns were started on ART later than those who had approximately normal gait patterns (mean age 11mo vs 7mo). Concerning overall clinical status at initiation of ART, almost all participants already had severe immune suppression and high viral loads (Fig. 1h, i) . Indeed, some individuals may have lived with advanced HIV disease for several months prior to this point. For example, Innes et al. reported that 63% of 403 South African infants initiated on ART by 3 months of age already had advanced HIV disease, with some infants having advanced disease as early as 6 weeks after birth. 22 It is possible that CD4 percentage or viral load values from within the first weeks of life may have provided greater insight into current functional status, but, unfortunately, such tests were not conducted.
It follows that current functional status is likely determined by multiple, complex factors, rather than primarily by factors related to the start of ART. Our study was limited by the fact that we did not have information about the timing of perinatal HIV infection, maternal viral load, or exposure to drug therapy for the prevention of mother-tochild transmission -factors which may also potentially contribute to functional status in children with HIVE and BLL spasticity. Our study was also limited by the small sample size and the fact that some children had benefited from prior orthopaedic surgery interventions (>12mo prior to participation) or regular physiotherapy (Table I) . However, it was noted that the aforementioned interventions were most common in children at GMFCS level III. In other words, the interventions did not appear to influence greatly relative functional ability within the study cohort.
CONCLUSION
In conclusion, the current study provides a novel description of functional status in children with HIVE and BLL spasticity and shows that gross motor function may range from minimal impairment to substantial limitations in standing, walking, running, and jumping. Differences in gross motor function could not be explained by the age, CD4 percentage, or viral load at initiation of ART in the current, small participant group. The functional status of children with HIVE and BLL spasticity is probably determined by multiple factors and further research with larger study cohorts is needed to shed light on these interactions. The impact of functional limitations on activity and participation in children with HIVE and BLL spasticity is unclear. However, the majority of the children in the current study were from a low socioeconomic setting where there may be difficulty in accessing therapeutic care and little provision in local environments for individuals with functional limitations. It follows that functional limitations may have a particularly large impact on quality of life in these children, highlighting the importance of follow-up and referral when a child presents with lower limb muscle tone abnormalities.
